Skip to main content
Premium Trial:

Request an Annual Quote

NeuMoDx Gets CE Mark on Hepatitis B and C Assays

NEW YORK – NeuMoDx confirmed today it has received CE-IVD marking on assays to detect and quantify levels of hepatitis B virus and hepatitis C virus. The two assays are now available in Europe.

The Ann Arbor, Michigan-based firm is focused on high-volume central laboratory customers, and the HBV and HCV tests could be particularly useful to labs serving immunocompromised populations or monitoring HBV DNA and HCV RNA titers for therapy management, the firm noted in a statement.

The NeuMoDx systems provide first results in one hour, with continuous sample loading and a random-access workflow with up to eight hours of walkaway time. They also use the firm's proprietary NeuDry reagents that do not require refrigeration, have a room temperature shelf life of more than one year, and an onboard stability of 60 days.  NeuMoDx also sells reagents and consumables for customers to create laboratory-developed tests on the systems.

"We are very pleased with our continued progress in expanding the menu on the first truly continuous random-access platform on the market," said Dan Harma, NeuMoDx chief commercial.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.